Phase 3 Recruiting NIH
This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) a…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06589804
Sites in North Carolina: - UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
- Margaret R Pardee Memorial Hospital — Hendersonville, North Carolina
- FirstHealth of the Carolinas-Moore Regional Hospital — Pinehurst, North Carolina
Phase 2, Phase 3 Recruiting Academic/Other
This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy s…
Sponsor: NRG Oncology
NCT ID: NCT04333537
Sites in North Carolina: - UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor recept…
Sponsor: AstraZeneca
NCT ID: NCT07431281
Sites in North Carolina: - Research Site — Charlotte, North Carolina
- Research Site — Wilmington, North Carolina
- Research Site — Winston-Salem, North Carolina
Phase 3 Recruiting Industry
This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.
Sponsor: Merus B.V.
NCT ID: NCT06525220
Sites in North Carolina: - Site 113 — Durham, North Carolina
- Site 118 — Winston-Salem, North Carolina
Phase 3 Recruiting Network
This study is being done to answer the following question: Is the chance of cancer spreading or returning the same if radiotherapy to the neck is guided, by using a special imaging study called lymph node mapping (lymphatic mapping) Single…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT05451004
Sites in North Carolina: - UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
Phase 3 Recruiting Industry
This is a global, open-label, randomized, 2-arm, Investigator's choice Phase 3 (Pivotal Stage) study to investigate the efficacy and safety of JNJ-90301900 (NBTXR3) / radiation therapy (RT)±cetuximab versus RT±cetuximab in treatment-naïve,…
Sponsor: Johnson & Johnson Enterprise Innovation Inc.
NCT ID: NCT04892173
Sites in North Carolina: - University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
- Atrium Health Levine Cancer Institute — Charlotte, North Carolina
Phase 2 Recruiting Network
This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-ra…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT02734537
Sites in North Carolina: - UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
- Southeastern Medical Oncology Center-Clinton — Clinton, North Carolina
- Southeastern Medical Oncology Center-Goldsboro — Goldsboro, North Carolina
- Wayne Memorial Hospital — Goldsboro, North Carolina
- Onslow Memorial Hospital — Jacksonville, North Carolina
Phase 2 Recruiting NIH
This phase II trial tests effects of nivolumab in combination with chemotherapy drugs prior to radiation therapy patients with nasopharyngeal carcinoma (NPC). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06064097
Sites in North Carolina: - Carolinas Medical Center/Levine Cancer Institute — Charlotte, North Carolina
- Duke University Medical Center — Durham, North Carolina
- East Carolina University — Greenville, North Carolina
- Wake Forest University Health Sciences — Winston-Salem, North Carolina
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in North Carolina: - Duke University — Durham, North Carolina
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383. The main questions if aims to answer are: * Does CP-383 slow or stop the growth of…
Sponsor: Tasca Therapeutics
NCT ID: NCT07030257
Sites in North Carolina: - Carolina BioOncology Institute — Huntersville, North Carolina
Phase 2 Recruiting Industry
DESTINY-Gastric03 will investigate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of trastuzumab deruxtecan (T-DXd) alone or in combination with chemotherapy and/or immunotherapy in HER2-expr…
Sponsor: AstraZeneca
NCT ID: NCT04379596
Sites in North Carolina: - Research Site — Durham, North Carolina
Phase 1, Phase 2 Recruiting Industry
Phase 1/2, open-label study of ETX-636 in participants with advanced solid tumors
Sponsor: Ensem Therapeutics
NCT ID: NCT06993844
Sites in North Carolina: - Carolina BioOncology Institute — Huntersville, North Carolina
Phase 2 Recruiting Federal
Esophageal cancer, which has a low 5-year overall survival rate (\<20%) is increasing in incidence. Previous studies have shown that Hedgehog, AKT, and angiogenic signaling pathways are activated in a significant number of esophageal cance…
Sponsor: VA Office of Research and Development
NCT ID: NCT05563766
Sites in North Carolina: - Durham VA Medical Center, Durham, NC — Durham, North Carolina
Phase 1, Phase 2 Recruiting Industry
This is a study to evaluate the safety and potential anti-tumor activity of an investigational drug called ARV-6723, in participants with advanced solid tumors. This is an open-label study which means that participants and study staff will…
Sponsor: Arvinas Inc.
NCT ID: NCT07749586
Sites in North Carolina: - Clinical Trial Site — Huntersville, North Carolina
Phase 2 Recruiting Academic/Other
This is a Phase II treatment, non-randomized, open label clinical trial to study the efficacy of the Cetuximab when administered as single agent in recurrent/ metastatic head and neck squamous cell carcinoma after the failure or intoleranc…
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT04375384
Sites in North Carolina: - Wake Forest Baptist Comprehensive Cancer Center — Winston-Salem, North Carolina
Phase 1 Recruiting Industry
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…
Sponsor: Exelixis
NCT ID: NCT05176483
Sites in North Carolina: - Exelixis Clinical Site #12 — Durham, North Carolina
Phase 1 Recruiting Industry
This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is …
Sponsor: Eli Lilly and Company
NCT ID: NCT07213791
Sites in North Carolina: - Duke University Medical Center — Durham, North Carolina
Phase 1 Recruiting NIH
This phase I/Ib trial tests the safety and best dose of ipatasertib in combination with the usual treatment approach using chemotherapy together with radiation therapy ("chemo-radiation") in patients with head and neck cancer. Ipatasertib …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05172245
Sites in North Carolina: - Carolinas Medical Center/Levine Cancer Institute — Charlotte, North Carolina
- Atrium Health Cabarrus/LCI-Concord — Concord, North Carolina
Phase 1 Recruiting Industry
This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic solid tumo…
Sponsor: Exelixis
NCT ID: NCT06545331
Sites in North Carolina: - Carolina BioOncology Institute — Huntersville, North Carolina
Phase 1 Recruiting Industry
The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driv…
Sponsor: Bicara Therapeutics
NCT ID: NCT04429542
Sites in North Carolina: - Levine Cancer Institute — Charlotte, North Carolina
Phase 1 Recruiting Industry
A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas
Sponsor: Dren Bio
NCT ID: NCT06999187
Sites in North Carolina: - Dren Investigational Site — Huntersville, North Carolina
Phase 1 Recruiting Industry
A multicenter, single-arm, first-in-human study to investigate the safety, pharmacokinetics, and preliminary antitumor activity of PLX-61639 in participants with locally advanced or metastatic, relapsed/refractory, SMARCA4-deficient solid …
Sponsor: Plexium, Inc.
NCT ID: NCT07284186
Sites in North Carolina: - Research Site — Durham, North Carolina
Phase 1 Recruiting Industry
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-711 as a monotherapy and in comb…
Sponsor: AbbVie
NCT ID: NCT07241039
Sites in North Carolina: - Carolina BioOncology Institute /ID# 272380 — Huntersville, North Carolina
Phase 1 Recruiting Academic/Other
This multicenter study examines the safety and feasibility of the combination of neoadjuvant XL092 and cemiplimab prior to surgical resection in participants with wild-type (WT) anaplastic thyroid cancer (ATC) that has a BRAF mutation (BRA…
Sponsor: UNC Lineberger Comprehensive Cancer Center
NCT ID: NCT06902376
Sites in North Carolina: - University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
Phase 1 Recruiting Academic/Other
The purpose of this study is to assess the safety and efficacy of the combination of D2C7-IT+2141-V11 administered in the non-enhancing tumor of patients with resected recurrent glioblastoma (rGBM) via convection enhanced delivery (CED), f…
Sponsor: Darell Bigner
NCT ID: NCT06455605
Sites in North Carolina: - Duke University Medical Center — Durham, North Carolina